0000000000383275

AUTHOR

Bernd L. Fiebich

showing 8 related works from this author

ChemInform Abstract: COX-1/COX-2 Inhibitors Based on the Methanone Moiety.

2010

ChemistryCox 1 cox 2MoietyGeneral MedicinePharmacologyChemInform
researchProduct

COX-1/COX-2 inhibitors based on the methanone moiety

2002

This paper focuses on the synthesis and the in vitro testing of dual COX-1/COX-2 inhibitors. Starting from structures of non-steroidal anti-inflammatory drugs (NSAIDs) the diaryl methanone element was chosen as a lead. Modifications were carried out on this scaffold to obtain potent inhibitors of the COX enzymes. The N-(2-aroylphenyl)sulphonamides and -amides were studied in detail, and to consolidate the data evaluated the corresponding 3- and 4-regioisomers were also investigated. The potency and the enzyme selectivity were varied by structural modifications of the lead.

Blood PlateletsStereochemistrymedicine.drug_classDrug Evaluation PreclinicalCarboxamideIsozymeChemical synthesisStructure-Activity RelationshipOxazinesDrug DiscoverymedicineAnimalsPotencyMoietyCyclooxygenase InhibitorsPharmacologychemistry.chemical_classificationCyclooxygenase 2 InhibitorsMolecular StructurebiologyChemistryAnti-Inflammatory Agents Non-SteroidalOrganic ChemistryGeneral MedicineIn vitroIsoenzymesEnzymeCyclooxygenase 2Prostaglandin-Endoperoxide SynthasesEnzyme inhibitorCyclooxygenase 1biology.proteinEuropean Journal of Medicinal Chemistry
researchProduct

Platelet micro-RNA expression in type 2 diabetes mellitus

2013

medicine.medical_specialtybusiness.industryInflammatory responseType 2 Diabetes Mellitusmedicine.diseaseMICROBIOLOGY PROCEDURESEndocrinologyInternal medicinePlatelet-rich plasmaDiabetes mellitusmicroRNAImmunologymedicinePlateletCardiology and Cardiovascular MedicinebusinessEuropean Heart Journal
researchProduct

The pyrrole moiety as a template for COX-1/COX-2 inhibitors

2000

Aroyl- and thiophene-substituted pyrrole derivatives have been synthesized as a new class of COX-1/COX-2 inhibitors. The inhibition of COX-1 was evaluated in a biological system using bovine PMNLs as the enzyme source, whereas LPS-stimulated human monocytes served as the enzyme source for inducible COX-2. The determination of the concentration of arachidonic acid metabolites was performed by HPLC for COX-1 and RIA for COX-2. Variation of the substitution pattern led to a series of active compounds which showed inhibition for COX-1 and COX-2. Structural requirements for the development of COX-1/COX-2 inhibitors are discussed.

DiclofenacNeutrophilsStereochemistryIndomethacinThiophenesHigh-performance liquid chromatographyMonocytesPyrrole derivativeschemistry.chemical_compoundDrug DiscoveryAnimalsHumansStructure–activity relationshipMoietyCyclooxygenase InhibitorsPyrrolesSulfonesPyrrolePharmacologychemistry.chemical_classificationArachidonic AcidCyclooxygenase 2 InhibitorsMolecular StructureAnti-Inflammatory Agents Non-SteroidalOrganic ChemistryMembrane ProteinsGeneral MedicineIsoenzymesEnzymechemistryMembrane proteinBiochemistryCyclooxygenase 2Prostaglandin-Endoperoxide SynthasesCyclooxygenase 1Leukocytes MononuclearCattleArachidonic acidEuropean Journal of Medicinal Chemistry
researchProduct

TYPE II DIABETES MELLITUS HAS NO MAJOR INFLUENCE ON PLATELET MICRO–RNA EXPRESSION: RESULTS FROM MICRO–ARRAY PROFILING IN A COHORT OF 60 PATIENTS

2013

Blood platelets represent pro–inflammatory mediators in the development of atherosclerosis. Diabetes mellitus as a major contributor to cardiovascular disease burden induces dysfunctional platelets. Platelets contain abundant miRNAs, which recently have been linked tightly to inflammation. While

business.industryInflammationMicro arraymedicine.diseaseType ii diabetesDiabetes mellitusCohortmicroRNAImmunologymedicinePlateletmedicine.symptomCardiology and Cardiovascular MedicinebusinessJournal of the American College of Cardiology
researchProduct

Traditionally used Thai medicinal plants: in vitro anti-inflammatory, anticancer and antioxidant activities.

2009

In order to assess traditional Thai claims about the therapeutic potential of medicinal plants and to select plants for future phytochemical research, nine plant species with anti-inflammatory uses were selected from Thai textbooks and assessed for their in vitro anti-inflammatory, antiproliferative and antioxidant activities.Nuclear factor-kappaB (NF-kappaB) inhibitory effects in stably transfected HeLa cells were determined by luciferase assay, and effects on LPS-induced pro-inflammatory mediators prostaglandin E2 (PGE2), interleukin (IL)-6, IL-1beta, and tumour necrosis factor (TNF)alpha in primary monocytes were assessed by ELISA. Cytotoxic activities were examined against HeLa cells, h…

DPPHmedicine.drug_classCell SurvivalInterleukin-1betaAnti-Inflammatory AgentsPharmacognosyAsteraceaeTransfectionAnti-inflammatoryAntioxidantsDinoprostoneMonocytesHeLachemistry.chemical_compoundInhibitory Concentration 50MagnoliopsidaPhenolsDrug DiscoveryMedicineHumansGynuraPharmacologyPlants MedicinalTraditional medicinebiologyDose-Response Relationship Drugbusiness.industryInterleukin-6Plant ExtractsTumor Necrosis Factor-alphaNF-kappa Bbiology.organism_classificationThailandOroxylum indicumAntineoplastic Agents PhytogenicPolygonaceaeRhinacanthus nasutusPhytochemicalchemistryDrug Resistance NeoplasmBignoniaceaeLipid PeroxidationMedicine TraditionalInflammation MediatorsbusinessHeLa CellsJournal of ethnopharmacology
researchProduct

Cyclooxygenase-1/2 (COX-1/COX-2) and 5-lipoxygenase (5-LOX) inhibitors of the 6,7-diaryl-2,3-1H-dihydropyrrolizine type

2003

A series of 6,7-diaryl-2,3-1H-dihydropyrrolizines was prepared as COX-1/COX-2 and 5-LOX inhibitors. The inhibition of COX-1 was evaluated using intact bovine platelets as the enzyme source, whereas LPS-stimulated human monocytes served as the enzyme source for inducible COX-2. The determination of arachidonic metabolites was performed by HPLC for COX-1 and RIA for COX-2. The balance between COX-1/COX-2 and 5-LOX inhibition can be shifted by modifying the substitution pattern of the phenyl moiety at the 6- and 7-position of the pyrrolizine nucleus. Structure-activity relationships are discussed.

Blood PlateletsRadioimmunoassayHigh-performance liquid chromatographyIsozymeMonocytesDrug DiscoverymedicineCox 1 cox 2AnimalsHumansMoietyStructure–activity relationshipPyrrolesPlateletLipoxygenase InhibitorsEnzyme InhibitorsChromatography High Pressure LiquidPharmacologychemistry.chemical_classificationbiologyChemistryOrganic ChemistryMembrane ProteinsGeneral MedicineIn vitroIsoenzymesmedicine.anatomical_structureEnzymeBiochemistryCyclooxygenase 2Prostaglandin-Endoperoxide SynthasesEnzyme inhibitorDrug DesignArachidonate 5-lipoxygenaseCyclooxygenase 1biology.proteinCattleCyclooxygenaseNucleusEuropean Journal of Medicinal Chemistry
researchProduct

ChemInform Abstract: The Pyrrole Moiety as a Template for COX-1/COX-2 Inhibitors.

2000

chemistry.chemical_compoundChemistryStereochemistryCox 1 cox 2MoietyGeneral MedicinePyrrole derivativesPyrroleChemInform
researchProduct